Company: PSTV
Filing Date: 2025-07-21
Form Type: DEF 14A
Source: 0001140361-25-026611
Chunk: 29

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-07-21
Form: DEF 14A
Chunk 29
---
 • | establishing base salary rates, benefits and other compensation matters for each of our executive officers; |

15

TABLE OF CONTENTS

| • | administering our equity compensation plans; |

| • | reviewing the relationship between our performance and our compensation policies and assessing any risks associated with such policies; |

| • | reviewing and advising the Board on director compensation matters and on regional and industry-wide compensation practices and trends in order to assess the adequacy of our executive compensation programs; and |

| • | reviewing and discussing compensation related disclosures with management and making a recommendation to the Board regarding the inclusion of such disclosures in our annual proxy statement or Form 10-K, as applicable. |

See the sections titled “Executive Compensation” and “Director Compensation” for a description of our processes and procedures for the consideration and determination of our executive officers and directors compensation. Nominating and Corporate Governance Committee Our Nominating and Corporate Governance Committee currently consists of Mr. Clowes, Dr. Lenk, and Dr. van Es-Johansson, each of whom our Board has determined is independent under the Nasdaq listing standards, a non-employee director and free from any relationship that would interfere with the exercise of his or her independent judgment. The Chairperson of our Nominating and Corporate Governance Committee is Dr. van Es-Johansson. Specific responsibilities of our Nominating and Corporate Governance Committee as provided in the Nominating and Corporate Governance Committee Charter include, among others:

| • | analyzing the expertise and experience of the Board and ensuring the membership of the Board consists of persons with sufficiently diverse and independent backgrounds; |

| • | identifying, recruiting, evaluating and recommending to the Board individuals qualified to become members of the Board; |

| • | establishing procedures for the consideration of candidates for the Board to recommended for the Nominating and Corporate Governance Committee’s consideration by Plus’s stockholders and recommending to the Board appropriate action on any such recommendation; |

| • | reviewing the Board committee structure and recommending to the Board changes to such structure; |

| • | reviewing and assessing the adequacy of our Corporate Governance Guidelines and recommending any proposed changes; |

| • | overseeing the annual self-evaluations of the Board and Board committees; |

| • | reviewing and discussing with management disclosures in our annual proxy statement regarding director independence; and |

| • | overseeing succession planning and processes for our Chief Executive Officer. |

Stockholder Communications with the Board Stockholders may contact an individual director, the Board as a group, or a specified Board committee or group